With Its R&D On Track, GSK R&D Chair Slaoui Cites Individual Responsibility, Culture As Success Factors

The Big Pharma did notably fewer deals in 2011, largely because of stringent criteria, reined in by a tight budget for R&D, but also because of its recent interest in external venture capital partners, some of which are not disclosed to the public.